Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.

HOME
>
論文・技術情報
>
Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.

アブストラクト	Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies in the Food and Drug Administration Adverse Event Reporting System. Myeloid and T-cell neoplasms were disproportionately more frequently reported, warranting further follow-up.
ジャーナル名	Blood
Pubmed追加日	2024/3/14
投稿者	Elsallab, Magdi; Ellithi, Moataz; Lunning, Matthew A; D'Angelo, Christopher; Ma, Jihyun; Perales, Miguel-Angel; Frigault, Matthew; Maus, Marcela V
組織名	Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA.;Cellular Immunotherapy Program, Mass General Cancer Center, and Department of;Medicine, Harvard Medical School, Boston, MA.;Fred & Pamela Buffett Cancer Center, Division of Hematology-Oncology, University;of Nebraska Medical Center, Omaha, NE.;Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE.;Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan;Kettering Cancer Center, New York, NY.;Department of Medicine, Weill Cornell Medical College, New York, NY.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/38483155/